Bangkok, Thailand – AstraZeneca Thailand announces the expansion of its pioneering AI Screening Project, extending its focus from lung cancer to include heart failure (HF) screening. This expansion, facilitated by strategic collaborations with six esteemed partners, marks a significant milestone in leveraging cutting-edge AI technology to improve early disease detection and patient outcomes. The AI Screening Project Expansion was unveiled at an impactful event held at Seacon Square Mall, Basement Floor, on December 13-14, 2024. Nearly 500 Thai people participated, benefitting from free AI-driven early screening services. This initiative underscores AstraZeneca's commitment to enhancing patient care through early detection, reinforcing the message "Don't Wait, Get Checked" for both lung cancer and high-risk heart failure patients.
The successful expansion of this project is powered by six key partnerships, each contributing unique expertise and resources: AstraZeneca and the QURE AI Team are leading the development and implementation of the AI screening project. The Digital Economy Promotion Agency (DEPA) provides digital technology integration and operational support, while the Banphaeo Hospital Team delivers invaluable medical expertise and on-site physician support. LINEMAN enhances accessibility with travel discounts for attendees visiting the shopping mall. The Department of Older Persons promotes health awareness among the elderly community, and Seacon Square Mall hosts the event to maximize public outreach and accessibility. This collaboration underscores the power of partnerships in driving healthcare innovation and making essential health services accessible to communities. By working together, these organizations are paving the way for a healthier future, empowering individuals to take proactive steps in managing their health.
This initiative is aligned with AstraZeneca's commitment to "Follow the Science" and "Put the Patient First," showcasing its leadership in integrating AI technology into healthcare solutions. By focusing on early disease detection and timely medical interventions, AstraZeneca continues to set new standards in patient care and healthcare innovation. We invite everyone to join us in this journey towards better health. Embrace the future of healthcare with AI-powered screening technologies that offer hope, inspiration, and empowerment. "Don't Wait, Get Checked" – take the first step towards a healthier tomorrow.
###
About AstraZeneca
AstraZeneca (Securities abbreviation, AZN on LSE/STO/Nasdaq stock exchanges) is a leading global biopharmaceutical company focusing on discovering, developing, and distributing medicines for medicinal purposes, particularly the group of drugs among cancer, heart disease, kidney, metabolic system, and respiratory disease. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and has millions of patients worldwide benefiting from its innovative medicines. For more information, please visit astrazeneca.com and follow the company on facebook.com/AstraZeneca.TH
For additional media information, please contact:
Cataliya Chalermvongsenee
Public Affairs and Communications Manager
Email: cataliya.chalermvongsenee@astrazeneca.com
Call: +66 (0) 80 064 8217
TH-21955
Expiration Date: 20/12/2026